{"protocolSection":{"identificationModule":{"nctId":"NCT02774278","orgStudyIdInfo":{"id":"BO18279"},"secondaryIdInfos":[{"id":"2004-005096-42","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients","acronym":"MERIT"},"statusModule":{"statusVerifiedDate":"2016-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-07"},"primaryCompletionDateStruct":{"date":"2009-06","type":"ACTUAL"},"completionDateStruct":{"date":"2009-06","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-03","studyFirstSubmitQcDate":"2016-05-12","studyFirstPostDateStruct":{"date":"2016-05-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-06-22","resultsFirstSubmitQcDate":"2016-06-22","resultsFirstPostDateStruct":{"date":"2016-08-02","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-08-05","lastUpdatePostDateStruct":{"date":"2016-08-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":264,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Erlotinib","type":"EXPERIMENTAL","description":"Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.","interventionNames":["Drug: Erlotinib"]}],"interventions":[{"type":"DRUG","name":"Erlotinib","description":"Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.","armGroupLabels":["Erlotinib"],"otherNames":["Tarceva"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Differentially Expressed Genes Associated With Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Clinical benefit is defined in the Outcome Measure 5.","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years"},{"measure":"Number of Epidermal Growth Factor Receptor (EGFR) Mutation Participants Who Achieved Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Number of participants with EGFR mutation (L858R/ exon 19 deletion) and who achieved clinical benefit status was reported. Clinical benefit is defined in the Outcome Measure 5.","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years"},{"measure":"Number of KRAS Mutation Participants Who Achieved Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Number of participants with KRAS gene mutation and who achieved clinical benefit status was reported. Clinical benefit is defined in the Outcome Measure 5.","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Overall Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST)","description":"Tumor response was defined as either a CR or a PR prior to failure (disease progression, death from any cause, or a second malignancy). CR was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. PR was defined as a greater than or equal to 50 percent (%) reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years"},{"measure":"Percentage of Participants With Clinical Benefit (CR, PR, or Stable Disease [SD] for at Least 12 Weeks After Study Entry) Using RECIST","description":"Clinical benefit was defined as either a CR, PR, or SD prior to failure (disease progression, death from any cause, or a second malignancy). CR: complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. PR: greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions. PD: unequivocal progression of existing non-target lesions.","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Advanced NSCLC\n* Tumor accessible for biopsy by bronchoscopy\n* Disease progression following course of standard chemotherapy, or participants unwilling/unable to undergo chemotherapy\n\nExclusion Criteria:\n\n* Unstable systemic disease\n* Any other malignancies in the last 5 years\n* Brain metastases\n* Previous treatment with therapy acting on the epidermal growth factor receptor (EGFR) axis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_CHAIR"}],"locations":[{"city":"Brussels","zip":"B-1200","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"city":"Sofia","zip":"1756","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"city":"Tallinn","zip":"11619","country":"Estonia","geoPoint":{"lat":59.43696,"lon":24.75353}},{"city":"Tartu","zip":"51014","country":"Estonia","geoPoint":{"lat":58.38062,"lon":26.72509}},{"city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"city":"Paris","zip":"75970","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Cologne","zip":"50937","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"city":"Gro√ühansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Dublin","zip":"8","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"city":"Perugia","zip":"06132","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"city":"Gdansk","zip":"80-214","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"city":"Lodz","zip":"94-306","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"city":"Lublin","zip":"20-950","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"107005","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Saint Petersburg","zip":"197089","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","zip":"198255","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Taipei","zip":"00112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Taipei","zip":"105","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Taipei","zip":"106","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Weston-super-Mare","zip":"BS23 4TQ","country":"United Kingdom","geoPoint":{"lat":51.34603,"lon":-2.97665}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"264"}]},{"type":"Safety Analysis Population (SAP)","achievements":[{"groupId":"FG000","comment":"SAP: all participants who received at least 1 dose of trial medication and had a safety follow-up.","numSubjects":"261"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"264"}]}],"dropWithdraws":[{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"199"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"Adverse event/intercurrent illness","reasons":[{"groupId":"FG000","numSubjects":"16"}]},{"type":"Refused treatment/did not cooperate","reasons":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"Administrative reasons","reasons":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis population included all enrolled participants.","groups":[{"id":"BG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"264"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.8","spread":"10.47"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"80"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"184"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Differentially Expressed Genes Associated With Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Clinical benefit is defined in the Outcome Measure 5.","populationDescription":"Primary analysis set (PAS) included all participants who provided evaluable tissue samples and were included in the primary Affymetrix efficacy analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"genes","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Epidermal Growth Factor Receptor (EGFR) Mutation Participants Who Achieved Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Number of participants with EGFR mutation (L858R/ exon 19 deletion) and who achieved clinical benefit status was reported. Clinical benefit is defined in the Outcome Measure 5.","populationDescription":"PAS participants who had EGFR mutation at baseline were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of KRAS Mutation Participants Who Achieved Clinical Benefit","description":"Affymetrix gene expression profiles were primarily analyzed to identify differentially expressed genes between the participants who derived clinical benefit status and those who did not. Analysis was performed using a multivariate linear model (with clinical benefit status, histology, ethnicity, sex, RNA integrity number (RIN), smoking status and stage as predictors), and a False Discovery Rate criteria of below 0.3 as cut-off. Number of participants with KRAS gene mutation and who achieved clinical benefit status was reported. Clinical benefit is defined in the Outcome Measure 5.","populationDescription":"PAS participants who had KRAS mutation at baseline were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST)","description":"Tumor response was defined as either a CR or a PR prior to failure (disease progression, death from any cause, or a second malignancy). CR was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. PR was defined as a greater than or equal to 50 percent (%) reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.","populationDescription":"Analysis population included all enrolled participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","lowerLimit":"11.1","upperLimit":"20.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Benefit (CR, PR, or Stable Disease [SD] for at Least 12 Weeks After Study Entry) Using RECIST","description":"Clinical benefit was defined as either a CR, PR, or SD prior to failure (disease progression, death from any cause, or a second malignancy). CR: complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. PR: greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions. PD: unequivocal progression of existing non-target lesions.","populationDescription":"Analysis population included all enrolled participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years","groups":[{"id":"OG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"264"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","lowerLimit":"25.9","upperLimit":"37.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 4 years","description":"Safety analysis population (SAP) included all participants who received at least one dose of the trial medication and had a safety follow-up.","eventGroups":[{"id":"EG000","title":"Erlotinib","description":"Erlotinib was administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.","seriousNumAffected":65,"seriousNumAtRisk":261,"otherNumAffected":209,"otherNumAtRisk":261}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":261}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":261}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":261}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Hydropneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":261}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":261}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pneumonia staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":261}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":261}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":261}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":261}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":261}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":261}]},{"term":"Haemorrhagic diathesis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":261}]},{"term":"Skin ulcer haemorrhage","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Arterial haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":261}]}],"otherEvents":[{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":133,"numAtRisk":261}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":261}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":261}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":261}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":84,"numAtRisk":261}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":261}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":261}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":261}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":261}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":261}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":261}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":261}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":261}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}